Keywords: Clavis Pharma, Clovis Oncology, CP-4126

Clavis Pharma and Clovis Oncology sign $380 million deal for anti-cancer agent CP-4126

Article | 26 November 2009

Norwegian oncology focussed Clavis Pharma and USA-based Clovis Oncology, the newly-formed oncology company led by former Pharmion Corp executives, have ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in